Want to stay updated on the latest news?
Create a Reader Account today to follow the industries and companies that interest you, and customize your news dashboard. SIGN INTO READER ACCOUNT CREATE READER ACCOUNT
MediciNova Announces Health Canada Grants Authorization to Commence Multi-arm Phase 2/3 Clinical Trial to Evaluate MN-166 (ibudilast) in Long COVID
February 08, 2023 18:00 ET
|
MediciNova, Inc.
LA JOLLA, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
PDS Biotech Announces Publication of Preclinical Infectimune™ Based Vaccine Studies Demonstrating Effective Protection Against Viral Infection in Peer-Reviewed Journal, Viruses
February 08, 2023 16:00 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Feb. 08, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
Diazyme SARS-CoV-2 Neutralizing Antibody Assay Receives Emergency Use Authorization
February 07, 2023 16:11 ET
|
General Atomics
SAN DIEGO, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Diazyme Laboratories, Inc. received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration on December 6, 2022, for use of the...
EnGeneIC publishes the COVID-EDV vaccine’s novel mechanism of action in a leading Immunology journal
January 31, 2023 13:46 ET
|
EnGeneIC
Protects against mutant strainsPromotes a long term memory responseNo side effects in healthy volunteersVaccine stored and transported at room temperature with long shelf lifeSeeking...
Dyadic Announces Initiation of Dosing of First-In-Human Phase 1 Trial to Demonstrate Clinical Safety and Antibody Response in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
January 24, 2023 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Kinarus Therapeutics Reports Preclinical Data in Lung Fibrosis and Discloses Clinical Development Plan
January 17, 2023 01:00 ET
|
Kinarus Therapeutic Holding AG
KIN001 reduced fibrotic damage of the lung in a preclinical fibrosis modelPotential as an effective oral therapy for Idiopathic Pulmonary Fibrosis (IPF)Phase 2 clinical trial in IPF patients in...
Veru Announces Appointment of Dr. David D. Ho as Chairman of its Infectious Disease Scientific Advisory Board
January 10, 2023 08:30 ET
|
Veru Inc.
MIAMI. FL, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for...
KRONOS® AIR DISINFECTION TECHNOLOGY MANUFACTURER RECEIVES FDA 510(K) CLASS II MEDICAL DEVICE CLEARANCE FOR THE DESTRUCTION OF VIRUSES, BACTERIA, AND ALLERGENS.
January 10, 2023 06:18 ET
|
Kronos Advanced Technologies Inc.
Parkersburg, WV, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Parkersburg, WV January 10, 2023 /Globenewswire/ KRONOS ADVANCED TECHNOLOGIES, INC. (OTC MARKETS: KNOS) ("KNOS" or the "Company"),...
Revive Therapeutics Announces Publication Showing Bucillamine’s Potential Impact on COVID-19 Omicron Variants
January 09, 2023 15:34 ET
|
Revive Therapeutics Ltd.
TORONTO, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Ocugen Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN™ (BBV152) in Phase 2/3 Immuno-bridging and Broadening Study: Both Co-primary Endpoints Met
January 09, 2023 06:00 ET
|
Ocugen
Study met both co-primary endpoints with robust immune responses COVAXIN™ was found to be well-tolerated in vaccine-naïve individuals and in individuals previously vaccinated with mRNA vaccines in the...